SCHEMBL25324531

SCHEMBL25324531

C[C@@H]1CNC(c2ccc3scnc3c2)CN1

nearest known ligand 0.34

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 2/20 0.34
▸ HSD17B10 Q99714 1/20 0.34
▸ PRMT5 O14744 2/20 0.33
▸ WDR77 Q9BQA1 1/20 0.33
▸ CRBN Q96SW2 2/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ RIPK2 O43353 4/20 0.32
▸ DYRK1A Q13627 4/20 0.31
▸ TGFBR1 P36897 4/20 0.31
▸ CLK4 Q9HAZ1 3/20 0.31
▸ DDB1 Q16531 1/20 0.31
▸ TRPM5 Q9NZQ8 1/20 0.31
▸ MAPK1 P28482 1/20 0.31
▸ SMN1; SMN2 Q16637 1/20 0.31
▸ NPSR1 Q6W5P4 1/20 0.31
▸ LCK P06239 3/20 0.31
▸ KDR P35968 3/20 0.31
▸ CLK1 P49759 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30522987 1.00 ALDH1A1 (0.34) ALDH1A1HSD17B10PRMT5WDR77CRBN
SCHEMBL25913598 1.00 ALDH1A1 (0.34) ALDH1A1HSD17B10PRMT5WDR77CRBN
SCHEMBL25327271 1.00 ALDH1A1 (0.34) ALDH1A1HSD17B10PRMT5WDR77CRBN
SCHEMBL25324534 1.00 ALDH1A1 (0.34) ALDH1A1HSD17B10PRMT5WDR77CRBN
SCHEMBL30470212 0.82 PRMT5 (0.39) ALDH1A1HSD17B10PRMT5WDR77SLC6A2
SCHEMBL30470799 0.82 PRMT5 (0.39) ALDH1A1HSD17B10PRMT5WDR77SLC6A2
SCHEMBL25320666 0.82 PRMT5 (0.39) ALDH1A1HSD17B10PRMT5WDR77SLC6A2
SCHEMBL25670004 0.82 PRMT5 (0.39) ALDH1A1HSD17B10PRMT5WDR77SLC6A2
SCHEMBL24365117 0.82 PRMT5 (0.39) ALDH1A1HSD17B10PRMT5WDR77SLC6A2
SCHEMBL31254514 0.80 METTL3 (0.34) ALDH1A1HSD17B10PRMT5WDR77SLC6A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250282749-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-09-11 — — US disclosed
EP-4469445-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
WO-2023146991-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250282749-A1 COMPOUNDS AND METHODS OF USE CYP1B1, CYP2C19, UGT1A1 ALDH1A1 193/4885HSD17B10 523/4885PRMT5 2082/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback